Abstract
Background The deviation between chronological age and age predicted using brain MRI is a putative marker of brain health and disease-related deterioration. Age prediction based on structural MRI data shows high accuracy and sensitivity to common brain disorders. However, brain aging is complex and heterogenous, both in terms of individual differences and the biological processes involved. Here, we implemented a multimodal age prediction approach and tested the predictive value across patients with a range of disorders with distinct etiologies and clinical features.
Methods We implemented a multimodal model to estimate brain age using different combinations of cortical area, thickness and sub-cortical volumes, cortical and subcortical T1/T2-weighted ratios, and cerebral blood flow (CBF) calculated from functional arterial spin labeling (ASL) data. For each of the 11 models we assessed the age prediction accuracy in HC n=761 and compared the resulting brain age gaps (BAGs) between each clinical group and age-matched subsets of HC in patients with Alzheimer’s disease (AD, n=54), mild cognitive impairment (MCI, n=88), subjective cognitive impairment (SCI, n=55), schizophrenia (SZ, n=156), bipolar disorder (BD, n=136), autism spectrum disorder (ASD, n=28).
Results Among the 11 models, we found highest age prediction accuracy in HC when integrating all modalities (mean absolute error=6.5 years). Beyond this global BAG, the area under the curve for the receiver-operating characteristics based on two-group case-control classifications showed strongest effects for AD and ASD in global T1-weighted BAG (T1w-BAG), while MCI, SCI, BD and SZ showed strongest effects in CBF-based BAGs.
Conclusions Combining multiple MRI modalities improves brain age prediction and reveals distinct deviations in patients with psychiatric and neurological disorders. The multimodal BAG was most accurate in predicting age in HC, while group differences between patients and controls were often larger for BAGs based on single modalities. These findings demonstrate that multidimensional phenotyping provides a mapping of overlapping and distinct pathophysiology in common disorders of the brain, and specifically suggest metabolic and neurovascular aberrations in SZ and at-risk and early stage dementia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study is supported by ERA-Net Cofund through the ERA PerMed project IMPLEMENT, the Research Council of Norway (223273, 249795, 248238, 276082, 286838, 298646, 300767), the South-Eastern Norway Regional Health Authority (2014097, 2015044, 2015073, 2016083, 2018037, 2018076, 2019101), the Norwegian ExtraFoundation for Health and Rehabilitation (2015/FO5146), the Novo Nordisk Foundation (NNF16OC0019856), KG Jebsen Stiftelsen, and the European Research Council under the European Union's Horizon 2020 research and Innovation program (ERC StG, Grant 802998).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Regional Committee for Medical Research Ethics and the Norwegian Data Inspectorate
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Due to ethical and data security issues related to the sensitive nature of the clinical data we are not allowed to share the data without specific IRB approval and data use agreements with the relevant institution. More information can be obtained through the corresponding author.
